Sprinkle coins every day

Chapter 456 Choose One?No, I want all the sprouts!

Monday, May 5.

Taking advantage of the presence of the presidents of the group's subsidiaries, Zhang Shuo personally presided over this week's meeting, which can be regarded as a rare offline group high-level meeting.

The newcomer, Sun Yang, the president of Lime Group, was the first to report.

"Previously, the chairman instructed that Lime Group's next goal is to get involved in the field of medical devices. It plans to choose one or two medical device companies with certain technical strength as acquisition targets."

"I have selected one here for everyone's discussion."

Sun Yang was very modest, and after a simple opening remark, he began to show the PPT.

"The company's name is Weichuang Medical, headquartered in Shanghai. It was founded in 98. It can be regarded as a relatively leading high-end medical device group in China."

"The founder, Dr. Chen, is an expert in the field of China's minimally invasive medical devices."

"The business under Victron Medical mainly covers the fields of cardiovascular interventional products, orthopedic medical devices, aortic and peripheral vascular interventional products, etc."

"Among them, relying mainly on cardiovascular interventional products, it is a leader in the field of minimally invasive medical devices."

"Weichuang has been listed in Xiangjiang for 10 years."

"The years before and after the listing were also the years of Vitron's great strides in development. In 08, Vitron Life Technology was established to enter the field of diabetes and start a diversified strategic layout."

"Weichuang Orthopedics was established in 09, Weichuang Electrophysiology was established in 10, and Weichuang Shentong, Weichuang Xinmai, and Weichuang Surgical Equipment were established in 12. Recently, I heard that Weichuang Medical is actively planning to establish Weichuang Medical Robot , Weichuang Online Medical Technology and other subsidiaries.”

"This step is a bit big, right?" Zhang Shuo frowned.

After listening to Sun Yang's introduction, he finally had a little impression of Weichuang, a medical company. The original time-space is a "cucurbit baby" model that spins off subsidiaries and packages them for listing, which has attracted much attention.

In addition to Weichuang Medical itself being listed in Xiangjiang, there are actually five listed companies under its umbrella.

Each listed company corresponds to a main business.

The problem is that, whether it is the new business developed by Vitron or the subsidiaries that are spun off and listed, most of them are in a state of loss. There are very few subsidiaries that can actually achieve profitability, all relying on blood transfusions from the parent company.

And the parent company is facing the risk of "hollowing out".

This also led to the saying that although Wei Chuang had a moment of prosperity in the stock market, it soon showed its prototype again.

"It's a little bit."

Sun Yang did not deny, "As far as I know, Dr. Chen is a very ambitious person. He wants to develop Vitron into a platform-based medical device group, so he chose a diversified development route. If only Vitron itself It is impossible to complete the diversification strategy without the strength of the company, and it needs the power of capital."

"Oh?"

Zhang Shuo raised his brows slightly, and understood what Sun Yang said.

Wei Chuang Medical has great ambitions, but its own strength is not enough, so it needs to rely on the power of external capital, and Lime Group is backed by the big tree of Germination, and the most important thing it lacks is capital.

The two can hit it off.

"What is the current market value of Weitron Medical, and what is its shareholding structure?" Zhang Shuo asked with concern.

"The current market value is about 65 billion, and the ownership structure is relatively concentrated. Except for the tradable shares in the market, the rest are mainly concentrated in the hands of a few major shareholders, including an investment company from Dongying."

Sun Yang obviously did his homework.

"65 billion, it's not expensive!"

Versailles is a rare occasion for Zhang Shuo. After all, with the current financial strength of the Germination Group, any acquisition with an amount of less than [-] billion can only be regarded as a small scene.

And if he remembers correctly, the market value of the original Space-Time Weichuang Medical was over 30 billion at its peak, even if it was underestimated, it still had a market value of [-] billion.

This does not include the other five listed companies that were independently spun off and listed.

You must know that the sum of the market value of these five spin-off listed companies also once approached the stock price of the parent company.The founder, Dr. Chen, even shouted the slogan of trillions of market value.

Although it's a bit bragging.
Regarding the future stock price of Weichuang, it means that even from a purely financial investment perspective, the acquisition of Weichuang is a relatively cost-effective deal.

At least not bad!

"Well, I have two requirements for the acquisition of Weichuang."

Zhang Shuo thought for a while and said, "First, the premise of the acquisition is that Weichuang will be delisted from the privatization of Xiangjiang. Second, it must be ensured that all the equity in the hands of the Dongying company will be taken down."

"If the board of directors of Wei Chuang is willing to accept these two conditions, then the acquisition process can be initiated."

In Zhang Shuo's inherent cognition, the stock market, market value and the like are actually very imaginary.

Taking the stock market in the beautiful country as an example, the market value of Tesla exceeded one trillion US dollars, and Weida also broke through 800 billion US dollars at one point. At its peak, it was several times, or even ten times, the market value of broadcasting.

But if you want to trade broadcasting for teshira, probably no one would be stupid enough to do so.

There are similar examples in China. For example, Linde New Energy of the original space-time had a market value of nearly 1.5 trillion at its peak, but the net profit attributable to the parent company was only about 150 billion.

It doesn't match at all.

To put it bluntly, stock prices are often irrational, playing with concepts, and most of the time they are out of touch with actual business conditions and become pure capital games.

Therefore, Zhang Shuo has never been enthusiastic about promoting the company to go public.

Of course, this is also related to his system blessing. He has basically never been short of money since the beginning of his business, and this is even more so after the subsequent game business is on the right track.

on the other hand.

It is also because of the rapid development of Bud, Zhang Shuo's net worth has skyrocketed too fast, he has no interest, nor does he need to evaluate his personal assets through the so-called market value, and compete for the title of the richest man.

It's a bit of a solitary seeking defeat.

Not only Wei Chuang wants to be privatized and delisted, but Hengrui Pharmaceuticals, which still maintains its listing status, Zhang Shuo also plans to complete the privatization of Hengrui Pharmaceuticals when the time is right in the future.

Of course, privatization does not mean that Lime Group will hold 100% of the shares.

Even if it is privatized, the main shareholders of Hengrui Pharmaceuticals headed by Sun Yang can still hold shares in Hengrui Pharmaceuticals, but they no longer need to be supervised by listed institutions.

It is no longer necessary to be responsible to investors and excessively pursue investment returns.

Instead, focus on research and development, based on the long-term strategy of enterprise development, rather than short-term benefits.Only in this way can Hengrui Pharma become one of the giants in the global pharmaceutical industry in the future.

"it is good!"

This time, it was Luo Changan, the investment director in charge of the group's investment business, who nodded in response.

After Lu Kai was promoted to the president of the group, Luo Changan took charge of the group's investment and mergers and acquisitions business, including early investigations, contacts, and even follow-up in the middle and late stages.

It's just that at the critical moment, Lu Kai is needed to act as the final word.

Similar to Zhang Shuo before.

Of course, Lu Kai is not just for nothing. Taking advantage of the topic of acquiring a medical device company, he took advantage of the situation and said, "Chairman, the Investment and Acquisition Department has also locked in a medical device company, which is local to Binhai City."

"Oh, tell me?"

With Wei Chuang's size, it may not be able to fully satisfy the appetite of Lime Group.

"Is such that."

Lu Kai opened the PPT with a smile, and introduced: "This company is called Marui Medical. It was founded in 91 and was listed on the beautiful country in 06. It became the first medical equipment company in China to be listed on the beautiful country."

It can be found that the old medical companies were basically established in the 90s.

"Mairui's main business covers the three major medical device fields of life information and support, in vitro diagnostics, and medical imaging, and gradually expands to animal medicine, minimally invasive surgery, orthopedic consumables and other fields."

"In the field of life information and support, the main products include monitors, defibrillators, anesthesia machines, ventilators, electrocardiogram machines, operating tables, operating lights, suspension bridges, infusion pumps, and overall solutions for operating rooms/intensive care units A series of instruments and solutions for life information monitoring and support, including surgical laparoscopic camera system, cold light source, insufflation machine, optical endoscope, minimally invasive surgical instruments and surgical consumables, etc. series of minimally invasive surgery products.”

"In the field of in vitro diagnostics, we mainly provide a series of fully automatic and semi-automatic in vitro diagnostic products for laboratories, clinics and hospitals, mainly including blood cell analyzers, biochemical analyzers, chemiluminescence immunoassay analyzers, coagulation analyzers, urine analysis Instruments, microbiological diagnostic systems, and related reagents to obtain clinical diagnostic information through the detection of human samples."

"In the field of medical imaging, the main products include ultrasonic diagnostic systems, digital X-ray imaging systems and PACS. In the field of ultrasonic diagnostic systems, we provide hospitals, clinics, imaging centers, etc. with a full range of ultrasonic diagnostic systems from high-end coverage to low-end, and Gradually subdivide special solutions for different clinical specialties such as radiation, obstetrics, interventional, emergency, anesthesia, critical care, liver fibrosis, etc. In the field of digital X-ray imaging, it mainly provides mobile, A variety of digital imaging solutions, including double-column and suspension."

"It can be said that Marian is the leading enterprise in the production of medical equipment in China."

"so smart?"

Zhang Shuo raised his brows slightly. He really didn't expect that there would be such a Big Mac in Binhai City.

"I have investigated the history of Marian's fortune, and since it went public in the beautiful country in 06, it has embarked on a crazy merger and acquisition journey, through mergers and acquisitions of related companies at home and abroad, to make up for its shortcomings in business."

Lu Kai explained with a smile.

"Especially in 08, 11, 12, 13, including this year, there were big mergers and acquisitions."

In the development process of medical device companies, mergers and acquisitions are one of the basic paths.Looking at the leading companies in the global medical device industry, without exception, they have grown into industry giants through mergers and acquisitions.

It can even be said that there are no mergers and acquisitions, no giants.

The reason is that from the perspective of product characteristics, the medical device industry has fragmentation and discrete manufacturing attributes. Not only are there large differences between various subdivisions, but also the speed of product technology change is relatively fast. The impact of new technologies on old technologies often has Subversive.

From a market point of view, the ceiling of the medical device segment is obvious.

If it is unable to further expand its own market share, fierce external competition will quickly reduce the market share, and only through mergers and acquisitions can it break through the ceiling of a single product.

The independent R&D and production of large medical device companies accounted for 40%, and the other 60% relied on acquisitions.

Just like the Vitron Medical just discussed, the process of dismantling subsidiaries and expanding new businesses is actually accompanied by a series of mergers and acquisitions.

And by no means to say that everything starts from scratch.

And the rise of Lime Group, why not?First, it made a big purchase of Hengrui Pharmaceuticals, and then it aimed at the two major medical device giants, Weitron and Marian.

just say.

The mergers and acquisitions of Wei Chuang and Marui are all small things. The acquisition target is likely to be hundreds of millions, and the maximum is more than one billion.

The essence is the same.

"According to this, Marian should be living a very healthy life, and he is a leader in the industry, would he be willing to be acquired by us?" Zhang Shuo asked.

"Marian is actually just superficial."

Since Lu Kai dared to propose the acquisition of Marian, he was naturally sure, and explained: "In fact, in the past one or two years, the development of Marian has encountered a bottleneck and touched the ceiling of development."

"This can be seen from the fact that the stock price of Marian has been flat since it was listed in Pretty Country."

"Although there is a great demand in the Huaxia medical device market, the local medical device industry chain has problems such as duplication of low-end production capacity and waste of production resources, and there is still an objective gap with the world's advanced level."

"Whether it is Vitron or Marian, they were engaged in the production of some relatively low-end medical device products at the beginning. Although they have made progress in the past few years, they are still struggling in the field of high-end medical devices."

"In particular, some core components, such as tubes and detectors of CT equipment, almost all rely on imports, and there is no bargaining power, which in disguise increases the procurement cost."

Such a situation is basically the same as that of the mobile phone and semiconductor industries.

It can be regarded as the helplessness of latecomers!

"Because the development is stuck in a bottleneck and the stock price is flat, the management of Marian already has the idea of ​​delisting from Meiliguo. One of the founders has even quit the daily management of Marian and turned to invest in the real estate industry."

The current real estate industry is still very popular.

"Coincidentally, the founder's real estate business is currently facing a crisis of tight capital chain. If we can offer a suitable price, we are sure to acquire the shares of Marian in his hand."

Compared with Vitron, Marian's shareholding structure is simpler.

Except for 30% of the tradable shares on the market, the remaining 70% of the shares are basically held by the three founders, who hold 32.2%, 31.3% and 6.5% of the shares respectively.

For founders who want to engage in real estate, the shareholding ratio is 31.3%.

"On the basis of acquiring the equity in the hands of the founder, if we can help Marian complete the privatization and delisting from the beautiful country stock market, then we can obtain the controlling stake in Marian."

"So it is."

Only then did Zhang Shuo suddenly realize, and asked with a smile, "What is the current market value of Marian?"

"In conversion, it's almost 180 billion. The total cost of acquiring the founder's shares, plus privatization and delisting, is about 120 billion."

As expected, Lu Kai had done enough homework.

"Okay, let's do it together."

Zhang Shuo is also arrogant, the acquisition of one is an acquisition, and the acquisition of two is also an acquisition.

"As I said before, if the group does not enter the pharmaceutical industry, it will be enough. Once it enters, it will definitely make a name for itself. Take the medical device field as an example, the positioning of Lime Group is not to dominate China itself, Instead, we want to compete with global medical giants such as Medtronic, Johnson, and Simon Medical.”

"The lowest, the lowest, whatever, but also to squeeze into the top ten global medical device giants."

This decides to say.

Since its inception, Lime Group has embarked on a path of opening and closing.

Independent research and development is of course very important, but whether it is the research and development of new drugs or new medical device products, it is a time-consuming task, and results cannot be seen in a short period of time.

The best way is mergers and acquisitions, and mergers and acquisitions on a global scale.

Because whether it is in the beautiful country or in Europe, there are a large number of small medical device companies. These companies have been focusing on cutting-edge technologies in certain fields for decades.

Once good technologies and products are developed, they will be acquired by big companies.

In China, many small medical device companies are eagerly waiting to go public before they have mature commercial products.

After listing, under the pressure of investors, in order to ensure profits, no longer invest in innovation.

How sad?

This is also one of the reasons why Zhang Shuo decided to let Mengya end in person.

At the current time point, there are not many restrictions on overseas mergers and acquisitions of Huaxia enterprises. If it is delayed for another three to five years, even if Mengya spends a lot of funds, it will probably be powerless.

Except for acquisitions.

For some time to come, robots will be widely used in the field of medical equipment, which is an excellent outlet for overtaking on curves, and Lime Group cannot miss it.

As for the layout in the field of robotics, Wali Zhizao is a good platform.

And of course the Fertile Soil Research Institute.

Therefore, the Germinal Group's involvement in the pharmaceutical industry does not mean that it is really unable to empower the Lime Group. There are still some cross-cutting fields that can produce chemical reactions.

And it's worth looking forward to!

"Ting!!!"

After listening to Zhang Shuo's speech, Sun Yang was both excited and stressed.

Needless to say, Sun Yang really realized that Lime Group will undoubtedly be a broader and more potential development platform than Hengrui Pharmaceutical's previous "small fights".

It can even be said that it has risen a big step.

Before coming to the headquarters in Binhai City, Sun Yang originally thought that the group headquarters would be cautious about whether to acquire Vitron, but unexpectedly, they would even buy the larger Marian.

If these two acquisitions are all implemented, Lime Group will definitely become the giant and leader in China's medical device field in one fell swoop, and it will not be one of them.

Even with the global medical device giants, you can break the wrist.

And Zhang Shuo's speech undoubtedly proved this point. Perhaps, from the beginning of Lime Group's birth, it was destined to shoulder the mission of challenging global pharmaceutical giants.

Just like the wheat grain group and the rice ear group under Germination have been doing the same.

How could Sun Yang not be excited?
But while excited, facing such an extremely difficult task, as the helm of the Qingning Group, Sun Yang is under a lot of pressure, which is also conceivable.

You know, in a powerful system like the Germinal Group, if you don't do well, you can only resign automatically.

There is absolutely no second choice!
Even if Sun Yang is one of the founders and major shareholders of Hengrui Pharmaceuticals, he does not have any privileges.

The key is.

The parent company has already allocated so many resources, if it is really not good, Sun Yang himself will have no face to stay in this position.

Must fight!
Thinking of this, Sun Yang was still a little excited, vaguely feeling like when he first started his business.

This is so rare!

But only half a month ago, Sun Yang was still debating whether to agree to the acquisition of Qingning Group, whether to join the Germination system, but hesitantly, not sure, whether it was the right choice.

At this moment, he was worried about gain and loss, for fear of being eliminated by Germination.

I'm afraid no one will believe it.

From this, it can be seen that inside the Germination Group, including Zhang Shuo, the soul of Germination, there is indeed a magical power that can make countless high-level talents willing to fight for it.

This is where the budding spiritual core lies! ! !
(End of this chapter)